高剂量干扰素β-1a对比低剂量方案治疗中重度COVID-19的随机对照试验方案
本研究为单中心、开放标签、随机对照、2臂平行组(1:1)临床试验,计划纳入100例RT-PCR或CT确诊的中重度COVID-19患者,比较高剂量干扰素β-1a联合洛匹那韦/利托那韦与低剂量干扰素β-1a联合洛匹那韦/利托那韦的疗效。主要结局为临床改善时间(七分类序贯量表改善2分或出院,以先发生者为准)。
要点
- 高剂量对比低剂量干扰素β-1a联合洛匹那韦/利托那韦治疗中重度COVID-19。
- 主要结局为七分类序贯量表改善2分或出院的时间。
- 计划随机100例,每组50例,采用区组随机化并分配隐藏。
核心结论
- 研究旨在评估高剂量干扰素β-1a对比低剂量干扰素β-1a(基础治疗方案)在中重度COVID-19确诊患者中的有效性。
研究设计与样本
- 单中心、开放标签、随机对照、2臂平行组(1:1比例)临床试验,计划随机100例患者。
- 纳入标准:年龄≥18岁,血氧饱和度≤93%或呼吸频率≥24,且至少具备一项临床表现(如体温≥37.8℃、咳嗽、呼吸困难等),症状急性发作≤14天。
- 排除标准包括拒绝参与、使用与洛匹那韦/利托那韦或干扰素β-1a有潜在相互作用的药物、ALT/AST>5倍正常上限、妊娠或哺乳期、近5年酒精或药物成瘾史、入院后1小时内插管者。
- 使用区组随机化(每区组3或6例),由统计学家生成序列并置入密封不透明信封,分配隐藏良好。
主要发现
- 主要结局为临床改善时间,即七分类序贯量表改善2分或出院(以先发生者为准)。
- 次要结局包括随机化至研究最后一天的全因死亡率、住院期间SPO2改善、住院时长、新发机械通气使用率及持续时间。
- 研究方案仍在完善中,正在尝试增加更多次要结局。
关键数值与推荐
- 主要结局:七分类序贯量表改善2分或出院的时间(以先发生者为准)。
- 样本量:计划随机100例,高剂量组50例,低剂量组50例。
- 干预组:洛匹那韦/利托那韦+高剂量干扰素β-1a;对照组:洛匹那韦/利托那韦+低剂量干扰素β-1a。
- 两组均接受标准治疗,包括必要的氧疗、无创或有创机械通气。
临床怎么用
- 该方案为COVID-19抗病毒及免疫调节治疗中干扰素剂量选择提供了随机对照研究框架。
- 结果为中重度COVID-19患者使用高剂量干扰素β-1a是否优于低剂量基础方案提供证据。
局限性
- 单中心、开放标签设计,未对患者和结果评估者设盲。
- 样本量较小(计划100例),可能影响统计效能。
- 方案中部分次要结局仍在完善中,尚未最终确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We will investigate the effectiveness of high dose Interferon Beta 1a, compared to low dose Interferon Beta 1a (the base therapeutic regimen) in COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed) with moderate to severe disease TRIAL DESIGN: This is a single center, open label, randomized, controlled, 2-arm parallel group (1:1 ratio), clinical trial. PARTICIPANTS: The eligibility criteria in this study is: age ≥ 18 years, oxygen saturation (SPO2) ≤ 93% or respiratory rate ≥ 24, at least one of the following manifestation: radiation contactless body temperature ≥37.8, Cough, shortness of breath, nasal congestion/ discharge, myalgia/arthralgia, diarrhea/vomiting, headache or fatigue on admission. The onset of the symptoms should be acute (≤ 14 days). The exclusion criteria include refusal to participate, using drugs with potential interaction with lopinavir/ritonavir or interferon-β 1a, blood ALT/AST levels > 5 times the upper limit of normal on laboratory results, pregnant or lactating women, history of alcohol or drug addiction in the past 5 years, the patients who be intubated less than one hours after admission to hospital. This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences. INTERVENTION AND COMPARATOR: COVID- 19 confirmed patients (using the RT-PCR test or CT scan) will be randomly assigned to one of two groups. The intervention group (Arms1) will be treated with lopinavir / ritonavir (Kaletra) + high dose Interferon-β 1a (Recigen) and the control group will be treated with lopinavir / ritonavir (Kaletra) + low dose Interferon-β 1a (Recigen) (the base therapeutic regimen). Both groups will receive standard care consisting of the necessary oxygen support, non-invasive, or invasive mechanical ventilation. MAIN OUTCOMES: Primary outcome: Time to clinical improvement is our primary outcome measure. This is an improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever comes first. SECONDARY OUTCOMES: mortality from the date of randomization until the last day of the study which will be the day all of the patients have had at least one of the following outcomes: 1) Improvement of two points on a seven-category ordinal scale. 2) Discharge from the hospital 3) Death. Improvement of SPO2 during the hospitalization, duration of hospitalization from date of randomization until the date of hospital discharge or death, whichever comes first. The incidence of new mechanical ventilation uses from the date of randomization until the last day of the study and the duration of it will be extracted. Please note that we are trying to add further secondary outcomes and this section of the protocol is still evolving. RANDOMIZATION: Eligible patients with confirmed SARS-Cov-2 infections will be randomly assigned in a 1:1 ratio to two therapeutic arms using permuted, block-randomization to balance the number of patients allocated to each group. The permuted block (three or six patients per block) randomization sequence will be generated, using Package 'randomizeR' in R software version 3.6.1. and placed in individual sealed and opaque envelopes by the statistician. The investigator will enroll the patients and only then open envelopes to assign patients to the different treatment groups. This method of allocation concealment will result in minimum selection and confounding biases. BLINDING (MASKING): The present research is open-label (no masking) of patients and health care professionals who are undertaking outcome assessment of the primary outcome - time to clinical improvement. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Of the 100 patients randomised, 50 patients will be assigned to receive high dose Interferon beta-1a plus lopinavir/ritonavir (Kaletra), 50 patients will be assigned to receive low dose Interferon beta 1a plus lopinavir/ritonavir (Kaletra). TRIAL STATUS: Protocol version 1.2.1. Recruitment is finished, the start date of recruitment was on August 20th 2020, and the end date was on September 4th 2020. Last point of data collection will be the last day on which all of the 100 participants have had an outcome of clinical improvement or death, up to 14th days after hospitalization. TRIAL REGISTRATION: This study was registered with National Institutes of Health Clinical trials ( www.clinicaltrials.gov ; identification number NCT04521400, https://clinicaltrials.gov/ct2/show/NCT04521400 , registered August 18, 2020 and first available online August 20, 2020). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Alavi Darazam I, Hatami F, Rabiei MM, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Trials. 2020. PMID: 33106183. doi:10.1186/s13063-020-04812-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。